Coagulation and Fibrinolytic System Impairment in Insulin Dependent Diabetes Mellitus
Overview
Affiliations
Selected coagulation and fibrinolytic parameters were assessed in 40 insulin dependent diabetes mellitus patients with varying degrees of metabolic control; 30 healthy subjects matched for age and sex formed the control group. Activated Partial Thromboplastin Time, Prothrombin Time, Fibrinogen, Factor VII, Antithrombin III, Protein C, Plasminogen, alpha 2-Plasmin Inhibitor, Plasminogen Activator Inhibitor-1, tissue-Plasminogen Activator were functionally evaluated. Antigenic levels of tissue-Plasminogen Activator, Thrombin-Antithrombin complexes and fibrinolytic specific product B beta 15-42 were also determined. Compared to the control group diabetic patients displayed significantly higher levels of Fibrinogen (p < 0.01), Factor VII (p < 0.01), Thrombin-Antithrombin complexes (p < 0.01) and Plasminogen Activator Inhibitor-1 activity (p < 0.01). Regardless of the normal level of the tissue-Plasminogen Activator-related antigen, diabetic patients had tissue-Plasminogen Activator activity lower than the control group (p < 0.05). Coagulation Factor VII and Thrombin-Antithrombin complexes were increased only in the patients with poor metabolic control (p < 0.01). Activated Partial Thromboplastin Time, Prothrombin Time, Antithrombin III, Protein C, Plasminogen, alpha 2-Plasmin Inhibitor, B beta 15-42 fibrin peptide were found to be in the normal range. Fibrinogen correlated positively with fasting blood glucose (p < 0.05) and Thrombin-Antithrombin complexes with glycosylated haemoglobin (p < 0.05), whereas Factor VII was positively correlated with glycemia (p < 0.01) and glycosylated haemoglobin (p < 0.05). Higher levels of Fibrinogen were found in patients affected by nephropathy (p < 0.005) or neuropathy (p < 0.05). These results demonstrate an impairment of the haemostatic balance in diabetic patients, that is a possible hypercoagulable state, which represents an important factor in the pathogenesis of atherosclerotic complications.
Getu F, Alemayehu E, Tesfaye A, Genanew B, Walle M Front Med (Lausanne). 2024; 11:1445031.
PMID: 39712180 PMC: 11658991. DOI: 10.3389/fmed.2024.1445031.
Valencia I, Lumpuy-Castillo J, Magalhaes G, Sanchez-Ferrer C, Lorenzo O, Peiro C Cardiovasc Diabetol. 2024; 23(1):75.
PMID: 38378550 PMC: 10880237. DOI: 10.1186/s12933-023-02097-8.
Inflammatory protein signatures in individuals with obesity and metabolic syndrome.
Mir F, Abdesselem H, Cyprian F, Iskandarani A, Doudin A, Samra T Sci Rep. 2023; 13(1):22185.
PMID: 38092892 PMC: 10719383. DOI: 10.1038/s41598-023-49643-8.
Yap E, Lijfering W, Timp J, Rosendaal F, Cannegieter S, Scheres L EJHaem. 2023; 4(1):3-12.
PMID: 36819164 PMC: 9928659. DOI: 10.1002/jha2.618.
Polat G, Gucsav M, Ozdemir O, Turk M, Serce Unat D, Tatar D Arch Endocrinol Metab. 2023; 67(3):341-347.
PMID: 36651707 PMC: 10247243. DOI: 10.20945/2359-3997000000544.